These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20700786)

  • 1. [Pharmacological neuroenhancement and brain doping : Chances and risks].
    Franke AG; Lieb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Aug; 53(8):853-9. PubMed ID: 20700786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Doping for the brain].
    Iglseder B
    Z Gerontol Geriatr; 2018 Feb; 51(2):143-148. PubMed ID: 29209802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.
    Gahr M; Connemann BJ; Schönfeldt-Lecuona C; Zeiss R
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects.
    Franke AG; Bagusat C; Rust S; Engel A; Lieb K
    Eur Arch Psychiatry Clin Neurosci; 2014 Nov; 264 Suppl 1():S83-90. PubMed ID: 25214391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological cognitive enhancement from a perspective of misuse and addiction].
    Franke AG; Soyka M
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):83-90. PubMed ID: 25723772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Case of Pharmacological Neuroenhancement: Medical, Judicial and Ethical Aspects from a German Perspective.
    Franke AG; Northoff R; Hildt E
    Pharmacopsychiatry; 2015 Nov; 48(7):256-64. PubMed ID: 26252723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review.
    Fond G; Micoulaud-Franchi JA; Brunel L; Macgregor A; Miot S; Lopez R; Richieri R; Abbar M; Lancon C; Repantis D
    Psychiatry Res; 2015 Sep; 229(1-2):12-20. PubMed ID: 26187342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulants for depression: On the up and up?
    Malhi GS; Byrow Y; Bassett D; Boyce P; Hopwood M; Lyndon W; Mulder R; Porter R; Singh A; Murray G
    Aust N Z J Psychiatry; 2016 Mar; 50(3):203-7. PubMed ID: 26906078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of university students using stimulants for cognitive enhancement: a pilot study].
    Franke AG; Schwarze CE; Christmann M; Bonertz C; Hildt E; Lieb K
    Psychiatr Prax; 2012 May; 39(4):174-80. PubMed ID: 22318482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroenhancement and mood enhancement – Physiological and pharmacodynamical background.
    Weiergräber M; Ehninger D; Broich K
    Med Monatsschr Pharm; 2017 Apr; 40(4):154-64. PubMed ID: 29952165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroenhancement: status quo and perspectives.
    Normann C; Berger M
    Eur Arch Psychiatry Clin Neurosci; 2008 Nov; 258 Suppl 5():110-4. PubMed ID: 18985306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Options, limits and ethics of pharmacological neuroenhancement].
    Normann C; Boldt J; Maio G; Berger M
    Nervenarzt; 2010 Jan; 81(1):66-74. PubMed ID: 19851745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.
    Daubner J; Arshaad MI; Henseler C; Hescheler J; Ehninger D; Broich K; Rawashdeh O; Papazoglou A; Weiergräber M
    Neural Plast; 2021; 2021():8823383. PubMed ID: 33519929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing the problem of ADHD medication as neuroenhancements.
    Graf WD; Miller G; Nagel SK
    Expert Rev Neurother; 2014 May; 14(5):569-81. PubMed ID: 24738763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of and motives for pharmacological neuroenhancement in Switzerland--results from a national Internet panel.
    Maier LJ; Haug S; Schaub MP
    Addiction; 2016 Feb; 111(2):280-95. PubMed ID: 26189457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuroenhancement].
    Gründer G; Bartsch T
    Nervenarzt; 2014 Dec; 85(12):1536-43. PubMed ID: 25403289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness.
    Killgore WD; Rupp TL; Grugle NL; Reichardt RM; Lipizzi EL; Balkin TJ
    J Sleep Res; 2008 Sep; 17(3):309-21. PubMed ID: 18522689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of executive function in ADHD.
    Swanson JM
    J Clin Psychiatry; 2003; 64 Suppl 14():35-9. PubMed ID: 14658934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuroenhancement in healthy subject? A French case study].
    Micoulaud-Franchi JA; Vion-Dury J; Lancon C
    Therapie; 2012; 67(3):213-21. PubMed ID: 22874487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.